Chemoradiation with 5-FU and Mitomycin C is the standard treatment in anal canal SCC.
Panitumumab has shown efficacy in other tumors and anti-EGFR treatment has shown clinical
activity in a single report of a refractory anal canal SCC patient. Based on this background,
we propose to conduct a phase II study to investigate the efficacy and toxicity of
radiotherapy with the association:
- 5-FU 1000mg/m2 on days 1-4 and 29-32
- Mitomycin C 10mg/m2 on days 1 and 29
- Panitumumab 6 mg/kg on day 1, then every 2 weeks for 8 weeks
Phase:
Phase 2
Details
Lead Sponsor:
Grupo Espanol Multidisciplinario del Cancer Digestivo